Trials & R&D · first seen 12h ago, updated 12h ago

Merck’s return to ophthalmology snags first success

1 outlet Merck & Co. (MSD)

Merck’s $1.3 billion upfront bet on EyeBio in 2024 is starting to pay off with an efficacy win, though analysts questioned safety results from a pivotal trial. The New Jersey drug giant ...

Summary from Endpoints News.

Coverage 1 article · 1 outlet

Endpoints News 12h ago
Merck’s return to ophthalmology snags first success